FURIN correlated with immune infiltration serves as a potential biomarker in SARS-CoV-2 infection-related lung adenocarcinoma.
Lian-Xiang LuoManshan LiJiating SuXinyue YaoHui LuoPublished in: Clinical and experimental medicine (2021)
FURIN, as a proprotein convertase, has been found to be expressed in a variety of cancers and plays an important role in cancer. In addition, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires FURIN to enter human cells. However, the role of FURIN in lung adenocarcinoma remains unclear. And the expression of SARS-CoV-2 related gene in lung adenocarcinoma has not been clarified. Therefore, in order to explore the prognostic value and mechanism of FURIN in lung adenocarcinoma, we performed bioinformatics analysis with Oncomine, Tumor Immune Estimation Resource, Gene Expression Profiling Interactive Analysis, human protein atlas, UALCAN, PrognoScan, Kaplan-Meier plotter, cBioPortal and LinkedOmics databases. And then we used GSE44274 in the GEO (Gene Expression Omnibus) database to analyze the expression of FURIN in LUAD patients who infected with SARS-CoV. FURIN was highly expressed in lung adenocarcinoma and was significantly associated with poor overall survival. FURIN expression was found to be correlated with six major permeable immune cells and with macrophage immune marker in LUAD patients. In addition, SARS-CoV-2 infection might affect the expression of FURIN. FURIN can be used as a promising biomarker for determining prognosis and immune infiltration in LUAD patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- poor prognosis
- gene expression
- end stage renal disease
- ejection fraction
- newly diagnosed
- binding protein
- genome wide
- coronavirus disease
- peritoneal dialysis
- bioinformatics analysis
- adipose tissue
- prognostic factors
- copy number
- emergency department
- dna methylation
- machine learning
- amino acid
- deep learning
- young adults
- squamous cell carcinoma
- single cell
- papillary thyroid
- squamous cell
- drug induced
- patient reported